The role of sodium-glucose co-transporter 2 protein inhibitors in heart failure: more than an antidiabetic drug?

References

• Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632–644.
   PubMedGoogle Scholar
• Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29–34. PMID: 4835750.
   PubMed Web of Science ®Google Scholar
• Fitchett DH, Udell JA, Inzucchi SE. Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Eur J Heart Fail. 2017;19(1):43–53. PMID: 27653447.
   PubMed Web of Science ®Google Scholar
• Cubbon RM, Woolston A, Adams B, et al. Prospective development and validation of a model to predict heart failure hospitalisation. Heart. 2014;100(12):923–929.
   PubMed Web of Science ®Google Scholar
• Writing Committee; Maddox TM, Januzzi JL, Allen LA, et al. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77(6):772–810. PMID: 33446410.
   PubMed Web of Science ®Google Scholar
• Kashiwagi A, Araki S, Maegawa H. Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients. J Diabetes Investig. 2021;12(1):6–20.
   PubMed Web of Science ®Google Scholar
• Perry RJ, Shulman GI. Sodium-glucose cotransporter-2 inhibitors: understanding the mechanisms for therapeutic promise and persisting risks. J Biol Chem. 2020;295(42):14379–14390.
   PubMed Web of Science ®Google Scholar
• Joshi SS, Singh T, Newby DE, et al. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart. 2021;107:1032–1038.
   PubMed Web of Science ®Google Scholar
• Zeng Q, Zhou Q, Liu W, et al. Mechanisms and perspectives of sodium-glucose co-transporter 2 inhibitors in heart failure. Front Cardiovasc Med. 2021;8:636152. PMID: 33644138; PMCID: PMC7902509.
   PubMed Web of Science ®Google Scholar
• Palmiero G, Cesaro A, Vetrano E, et al. Impact of SGLT2 inhibitors on heart failure: from pathophysiology to clinical effects. Int J Mol Sci. 2021;22(11):5863.
   PubMed Web of Science ®Google Scholar
• Packer M. Cardioprotective effects of sirtuin-1 and its downstream effectors: potential role in mediating the heart failure benefits of SGLT2 (sodium-glucose cotransporter 2) inhibitors. Circ Heart Fail. 2020;13(9):e007197. PMID: 32894987.
   PubMed Web of Science ®Google Scholar
• Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care. 2020;43(3):508–511. PMID: 32079684.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. PMID: 31535829.
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al.; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424. PMID: 32865377.
   PubMed Web of Science ®Google Scholar
• Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019;139(22):2528–2536. PMID: 30882238.
   PubMed Web of Science ®Google Scholar
• Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019;140(18):1463–1476. PMID: 31524498.
   PubMed Web of Science ®Google Scholar
• Kambara T, Shibata R, Osanai H, et al. Importance of sodium-glucose cotransporter 2 inhibitor use in diabetic patients with acute heart failure. Ther Adv Cardiovasc Dis. 2019;13:1753944719894509.
   Google Scholar
• Bhatt DL, Szarek M, Steg PG, et al.; SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–128. PMID: 33200892.
   PubMed Web of Science ®Google Scholar
• Petrie MC, Verma S, Docherty KF, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323(14):1353–1368.
   PubMed Web of Science ®Google Scholar
• Soga F, Tanaka H, Tatsumi K, et al. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol. 2018;17(1):132. PMID: 30296931; PMCID: PMC6174555.
   PubMedGoogle Scholar
• Matsutani D, Sakamoto M, Kayama Y, et al. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):73.
   PubMedGoogle Scholar
• Shim CY, Seo J, Cho I, et al. Randomized, controlled trial to evaluate the effect of dapagliflozin on left ventricular diastolic function in patients with type 2 diabetes mellitus: the IDDIA trial. Circulation. 2021;143(5):510–512. PMID: 33186508.
   PubMed Web of Science ®Google Scholar
• Tadic M, Sala C, Saeed S, et al. New antidiabetic therapy and HFpEF: light at the end of tunnel? Heart Fail Rev. 2021. PMID: 33843015. doi:https://doi.org/10.1007/s10741-021-10106-9
   Google Scholar
• Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451–1461. PMID: 34449189.
   PubMed Web of Science ®Google Scholar
• Chen HY, Huang JY, Siao WZ, et al. The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study. Cardiovasc Diabetol. 2020;19(1):73. PMID: 32503541; PMCID: PMC7275510.
   PubMed Web of Science ®Google Scholar
• Hwang IC, Cho GY, Yoon YE, et al. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients. Cardiovasc Diabetol. 2020;19(1):69. PMID: 32466760; PMCID: PMC7254690.
   PubMed Web of Science ®Google Scholar
• Mordi NA, Mordi IR, Singh JS, et al. Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF trial. Circulation. 2020;142(18):1713–1724.
   PubMed Web of Science ®Google Scholar
• Milder TY, Stocker SL, Day RO, et al. Potential safety issues with use of sodium-glucose cotransporter 2 inhibitors, particularly in people with type 2 diabetes and chronic kidney disease. Drug Saf. 2020;43(12):1211–1221.
   PubMed Web of Science ®Google Scholar
• Seong JM, Kim JJ, Kim HJ, et al. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study. Cardiovasc Diabetol. 2020;19(1):95.
   PubMed Web of Science ®Google Scholar
• Kosiborod M, Cavender MA, Fu AZ, et al.; CVD-REAL Investigators and Study Group*. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136(3):249–259. PMID: 28522450; PMCID: PMC5515629.
   PubMed Web of Science ®Google Scholar
• Patorno E, Goldfine AB, Schneeweiss S, et al. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ. 2018;360:k119. PMID: 29437648; PMCID: PMC5799855.
   PubMedGoogle Scholar
• Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573. PMID: 33441402; PMCID: PMC7804890.
   PubMedGoogle Scholar
• Neuen BL, Arnott C, Perkovic V, et al. Sodium-glucose co-transporter-2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes. Diabetes Obes Metab. 2021;23(2):382–390.
   PubMed Web of Science ®Google Scholar
• Salah HM, Al’Aref SJ, Khan MS, et al. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials. Am Heart J. 2021;232:10–22. PMID: 33214130.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al.; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. PMID: 32970396.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al.; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. PMID: 30990260.
   PubMed Web of Science ®Google Scholar